Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Trial Profile

A Parallel Group Phase I/II Marker Lesion Study to Assess the Safety, Tolerability and Efficacy of Intravenous or Intravesical Pembrolizumab in Intermediate Risk Recurrent Non-muscle Invasive Bladder Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms PemBla
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 14 Sep 2017 Planned End Date changed from 1 Apr 2021 to 1 Aug 2021.
    • 14 Sep 2017 Planned primary completion date changed from 1 May 2019 to 1 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top